ICVTS Click here to goto Smart Canula website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Interact CardioVasc Thorac Surg 2009;8:449-453. doi:10.1510/icvts.2008.181362
© 2009 European Association of Cardio-Thoracic Surgery

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Petar S. Risteski
Sven Martens
Gerhard Wimmer-Greinecker
Anton Moritz
Mirko Doss
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Risteski, P. S.
Right arrow Articles by Doss, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Risteski, P. S.
Right arrow Articles by Doss, M.

Follow-up papers - Valves

Prospective randomized evaluation of stentless vs. stented aortic biologic prosthetic valves in the elderly at five years

Petar S. Risteski*, Sven Martens, Amin Rouhollahpour, Gerhard Wimmer-Greinecker, Anton Moritz and Mirko Doss

Department of Thoracic and Cardiovascular Surgery, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany

*Corresponding author. Tel.: +49 69 6301 5850; fax: +49 69 6301 5849.

E-mail address: docpsr{at}yahoo.com (P.S. Risteski).

Objectives: Randomized trials comparing stentless to stented bioprostheses for aortic valve replacement in elderly are scarce. The aim of this study was early and mid-term evaluation of these bioprostheses, with regards to clinical outcome and hemodynamic performance. Methods: Between September 1999 and January 2001, 40 patients with aortic stenosis, over the age of 75 years, were randomly assigned to receive either the stented Perimount (n=20) or the stentless Prima Plus (n=20) bioprosthesis. Clinical outcomes, left ventricular mass regression, effective orifice area, ejection fraction and mean gradients were evaluated at discharge, six months, one year and five years after surgery. Results: At five years, there were 5/20 (25%) deaths in the stentless group and 6/20 (30%) deaths in the stented group (all non-valve-related). There was one case of endocarditis in each group, early postoperatively. Overall, a significant decrease in left ventricular mass was found five years postoperatively. However, there was no significant difference in the rate and completeness of LV-mass regression between the groups (LV mass index 114±34.1 vs. 120±27.2). Furthermore, hemodynamic performance of the valves (mean gradient of 9.9±4.8 mmHg vs. 10.2±4.2 mmHg) did not differ significantly between the groups. Conclusions: At five years, stentless valves were not superior to the stented valves, with regards to hemodynamic performance, regression of left ventricular mass and clinical outcome.

Key Words: Aortic valve replacement; Heart valve; Bioprosthesis; Stentless valve







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 European Association for Cardio-thoracic Surgery